A Phase 3 interventional study of Fluticasone Propionate in Nasal Polyposis, sponsored by Optinose US Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-03.
Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.
Among the 83 studies in Nasal Polyps with a site in United States, this one is the 63rd largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2018, is one of 25 in phase 3, and was the 44th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Japan, Puerto Rico
Ages 18+
GlaxoSmithKline · Sites in United States, Australia
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Airiver Medical, Inc. · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 27 · Phase 4 10
First in 2005; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 60 across the 71 interventional studies, 35 across the 12 observational. Of the 54 that completed or were terminated, 41 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 83 have an industry lead sponsor. The 10 most frequent:
Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Optinose US Inc. has 4 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
8 of the studies in Nasal Polyps with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07681973The Cleveland ClinicCognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training | 2026-12-31 |
| NCT07286201Polyganics BVEvaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF) | 2027-03 |
| NCT07599826Cedars-Sinai Medical CenterActive vs. Passive VR During Office-based ENT Procedures | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 83 studies in Nasal Polyps with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.
The primary objective of this study is to evaluate the efficacy and safety of OPN-375 186 μg twice a day in adults with Bilateral Nasal Polyps using Nasoendoscopic video. The secondary objectives of this study are to evaluate the safety of OPN-375 via adverse event reports, vital signs, and nasal examination. In addition, to measure any change in subject symptoms and functioning from Baseline to 12 and 24 weeks during the study, using the Sinonasal Outcome Test -22 (SNOT-22), Patient's Global Impression of Change (PGIC), and measurement of nasal polyps by independent, blinded reader, and any changes throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of child bearing potential must be abstinent, or if sexually active,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fluticasone Propionate
OPN-375 186 μg BID, Delivered via exhalation delivery system
Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video
: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Time frame: Week 24
Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests
Time frame: 24 Weeks, up to 30 days after last dose
Assessment for Safety Through Nasal Examination
Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma
Time frame: 24 Weeks, up to 30 days after last dose
Assessment for Safety From Recording Vital Sign - Blood Pressure
Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)
Time frame: Baseline, Week 12, Week 24
Assessment for Safety From Recording Vital Sign - Pulse
measure pulse in beats per minute (bpm)
Time frame: Baseline, Week 12, Week 24
Assessment for Safety From the Collection of Information for Concomitant Medications Usage
Time frame: 24 Weeks, up to 30 days after last dose
Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Time frame: Week 24
Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Time frame: Week 24
Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Time frame: Week 24
Sinonasal Outcome Test 22 (SNOT-22) Total Score
SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as can be
Time frame: Week 24
Sniffin' Sticks N-butanol Test
The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.
Time frame: Week 24
Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved
The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)
Time frame: Week 24
| Milestone | OPN-375 186 mcg BID |
|---|---|
| Started | 11 |
| Completed | 9 |
| Not completed | 2 |
: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
| units on a scale | OPN-375 186 mcg BID |
|---|---|
| Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video | -0.7 ± 0.9 |
| Participants | OPN-375 186 mcg BID |
|---|---|
| Asthma | 1 |
| Back pain | 1 |
| Dizziness | 1 |
| Dyspnoea | 1 |
| Fungal skin infection | 1 |
| Hypotension | 1 |
| Influenza | 1 |
| Lacrimation increased | 1 |
| Nasal discharge discolouration | 1 |
| Sinusitis | 1 |
| Tension headache | 1 |
| Upper respiratory tract infection | 1 |
| Vasomotor rhinitis | 1 |
Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma
| Participants | OPN-375 186 mcg BID |
|---|---|
| Epistaxis | 1 |
| Septal erosion/perforation | 0 |
| Ulceration/erosion | 0 |
Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)
| mmHg | OPN-375 186 mcg BID - Systolic BP | OPN-375 186 mcg BID - Diastolic BP |
|---|---|---|
| Baseline | 130.1 ± 14.3 | 83.3 ± 9.3 |
| Week 12 | 127.4 ± 19.6 | 82.0 ± 12.9 |
| Week 24 | 131.9 ± 18.8 | 81.4 ± 8.7 |
measure pulse in beats per minute (bpm)
| bpm | OPN-375 186 mcg BID |
|---|---|
| Baseline | 71.5 ± 7.1 |
| Week 12 | 73.5 ± 9.1 |
| Week 24 | 76.4 ± 7.4 |
| Participants | OPN-375 186 mcg BID |
|---|---|
| ACE Inhibitor | 1 |
| Angiotensin II Receptor Antagonist | 1 |
| Antianginal | 1 |
| Anticoagulant | 1 |
| Antihistamine | 4 |
| Antifungal Cream | 1 |
| Ascorbic Acid | 1 |
| Beta Blocking Agent, selective | 2 |
| Beta2 Adrenergic Agonist | 6 |
| Biguanide | 1 |
| Calcium Channel Blocker | 1 |
| CNS Muscle Relaxant | 1 |
| Diuretic | 2 |
| Electolytes | 1 |
| HMG CoA Reductase Inhibitors | 1 |
| Inhaled Corticosteroid | 2 |
| Inhaled Corticosteroid/Long-acting beta-agonist | 6 |
| Leukotriene Receptor Antagonists | 3 |
| Multivitamin | 2 |
| Nitrate | 1 |
| Non-steroidal anti-inflammatory drug | 3 |
| Nuclear factor erythroid-2-related factor | 1 |
| Selective serotonin reuptake inhibitor | 1 |
| Synthetic nucleoside analogue | 1 |
| Other analgesics | 1 |
| Other antiinflammatorys | 1 |
| Topical antibiotics | 2 |
| Proton pump inhibitors | 1 |
| Testosterone | 1 |
| Thyroid Hormone | 2 |
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
| units on a scale | OPN-375 186 mcg BID |
|---|---|
| Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities) | 2.4 (2 to 4) |
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
| Participants | OPN-375 186 mcg BID |
|---|---|
| Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade | 5 |
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
| Participants | OPN-375 186 mcg BID |
|---|---|
| Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit | 1 |
SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as can be
| units on a scale | OPN-375 186 mcg BID |
|---|---|
| Sinonasal Outcome Test 22 (SNOT-22) Total Score | 27.8 ± 16.1 |
The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.
| units on a scale | OPN-375 186 mcg BID |
|---|---|
| Sniffin' Sticks N-butanol Test | 16.5 ± 6.9 |
The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)
| Participants | OPN-375 186 mcg BID |
|---|---|
| Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved | 9 |
Collected over 24 weeks, and up to 30 days after the last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPN-375 186 mcg BID | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Event | OPN-375 186 mcg BID |
|---|---|
| DyspneaCardiac disorders | 1/11 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/11 |
| Back PainMusculoskeletal and connective tissue disorders | 1/11 |
| DizzinessNervous system disorders | 1/11 |
| Fungal Skin InfectionInfections and infestations | 1/11 |
| HypotensionCardiac disorders | 1/11 |
| InfluenzaInfections and infestations | 1/11 |
| Lacrimation IncreasedEye disorders | 1/11 |
| Nasal Discharge DiscolourationRespiratory, thoracic and mediastinal disorders | 1/11 |
| SinusitisInfections and infestations | 1/11 |
| Age, Continuous(years) | OPN-375 186 mcg BID |
|---|---|
| Mean | 54.6 ± 14.5 |
| Sex: Female, Male(Participants) | OPN-375 186 mcg BID |
|---|---|
| Female | 3 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | OPN-375 186 mcg BID |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | OPN-375 186 mcg BID |
|---|---|
| United States | 11 |
| Total Polyp Grading Score (sum of scores from both nasal cavities)(units on a scale) | OPN-375 186 mcg BID |
|---|---|
| Mean | 3.1 (2 to 6) |
| Sinonasal Outcome Test 22 (SNOT-22) Total Score(units on a scale) | OPN-375 186 mcg BID |
|---|---|
| Mean | 48.8 (26 to 74) |
| Sniffin' Sticks n-butanol tests(units on a scale) | OPN-375 186 mcg BID |
|---|---|
| Mean | 11.8 ± 6.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Feb 2019, 8 months.
Results were first posted in Aug 2020, 1 year 5 months after primary completion.
Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Optinose US Inc.